Mepirid

Glimepiride, the active ingredient in Mepirid, is a second‑generation sulfonylurea presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults.\n\nGNH India supplies Mepirid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Glimepiride is indicated for the management of type 2 diabetes mellitus, a chronic disorder of glucose metabolism.\n\n- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose by stimulating insulin release.\n- Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when used with metformin or other oral agents.\n- Type 2 diabetes mellitus (adjunct to diet and exercise): helps patients achieve target HbA1c when lifestyle measures alone are insufficient.

Glimepiride may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Hypoglycaemia: feeling of low blood sugar, dizziness or sweating.\n- Weight gain: modest increase in body weight.\n- Nausea: mild stomach upset.\n- Headache: transient cranial discomfort.\n\nSerious or Rare Side Effects:\n- Severe hypoglycaemia: can lead to loss of consciousness or seizures.\n- Allergic reactions: rash, pruritus or angio‑edema.\n- Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Before initiating therapy, several safety considerations should be reviewed.\n\n- Renal impairment: dose adjustment or avoidance may be required.\n- Hepatic impairment: use with caution, monitor liver function.\n- Elderly patients: increased susceptibility to hypoglycaemia; start at low dose.\n- Concomitant sulfonylureas: avoid duplicate therapy to prevent excess insulin release.\n- Pregnancy and lactation: safety not established; generally contraindicated.\n- Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Glimepiride interacts with several drug classes that can alter its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Other sulfonylureas: additive risk of severe hypoglycaemia.\n- Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase plasma concentrations.\n- Concurrent insulin therapy: may precipitate profound hypoglycaemia.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers: may mask hypoglycaemia symptoms.\n- Thiazide diuretics: can attenuate glucose‑lowering effect.\n- Alcohol: may potentiate hypoglycaemia, especially with irregular intake.